Effect of Rifampicin and CYP2B6 Genotype on Long-Term Efavirenz Autoinduction and Plasma Exposure in HIV Patients With or Without Tuberculosis
- 3 August 2011
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 90 (3) , 406-413
Abstract
We performed a prospective comparative study to examine, from a pharmacogenetics perspective, the effect of rifampicin (RIF) on long-term efavirenz (EFV) autoinduction and kinetics. In a study population of patients with HIV receiving EFV with RIF (arm 2, n = 54) or without RIF (arm 1, n = 128 controls), intraindividual and interindividual plasma EFV and 8-hydroxyefavirenz levels were compared at weeks 4 and 16 of EFV therapy. In arm 2, RIF was initiated 4 weeks before starting EFV. In controls (arm 1), the plasma EFV was significantly lower whereas 8-hydroxyefavirenz was higher at week 16 as compared to week 4. By contrast, there were no significant differences in plasma EFV and 8-hydroxyefavirenz concentrations over time in arm 2. At week 4, the plasma EFV concentration was significantly lower in arm 2 as compared to arm 1, but no significant differences were observed by week 16. When stratified by CYP2B6 genotype, significant differences were observed only with respect to CYP2B6*1/*1 genotypes. Ours is the first report of the CYP2B6 genotype-dependent effect of RIF on long-term EFV autoinduction.Keywords
This publication has 35 references indexed in Scilit:
- Contribution of N-Glucuronidation to Efavirenz EliminationIn Vivoin the Basal and Rifampin-Induced Metabolism of EfavirenzAntimicrobial Agents and Chemotherapy, 2011
- Paradoxically elevated efavirenz concentrations in HIV/tuberculosis-coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapyAIDS, 2011
- No Evidence for Induction of ABC Transporters in Peripheral Blood Mononuclear Cells in Humans after 14 Days of Efavirenz TreatmentAntimicrobial Agents and Chemotherapy, 2010
- Efavirenz Primary and Secondary Metabolism In Vitro and In Vivo: Identification of Novel Metabolic Pathways and Cytochrome P450 2A6 as the Principal Catalyst of Efavirenz 7-HydroxylationDrug Metabolism and Disposition, 2010
- A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single‐dose efavirenz population pharmacokinetics in UgandansBritish Journal of Clinical Pharmacology, 2009
- CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patientsAIDS, 2009
- Glucuronidation of the Antiretroviral Drug Efavirenz by UGT2B7 and an in Vitro Investigation of Drug-Drug Interaction with ZidovudineDrug Metabolism and Disposition, 2009
- Influence of the Cytochrome P450 2B6 Genotype on Population Pharmacokinetics of Efavirenz in Human Immunodeficiency Virus PatientsAntimicrobial Agents and Chemotherapy, 2009
- Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis controlAIDS, 2006
- Pharmacokinetic Interactions Between Efavirenz and Rifampicin in HIV-Infected Patients with TuberculosisClinical Pharmacokinetics, 2002